Sotera Health Company Common Stock (SHC) Stock Price
SHCStock
$17.89+9.55%52W
Market Cap$5.11B
P/E65.50x
PEG Ratio1.31
Div yield—
Beta1.94
SHC Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)2.40%
Price vs S&P 500 (4W)-3.01%
PEG Ratio1.31
VGM Score48.86
P/E Ratio (Annual)65.50x
SHC Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | $0.24 | $0.26 | +8.70%(+$0.02) | |
| Q1 2026 | $0.17 | $0.18 | +3.36%(+$0.01) | |
| Q4 2025 | $0.24 | $0.26 | +7.05%(+$0.02) | |
| Q3 2025 | $0.22 | $0.26 | +19.13%(+$0.04) | |
| Q2 2025 | $0.17 | $0.20 | +15.87%(+$0.03) |
SHC Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.20
4.13
4.13
4.13
Industry Peers — Health Services(17)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
SHCSotera Health Company Common Stock | D | B | C | 65.5x | 8.2% | 32.6% | 26.8% | $17.89 |
| DVADaVita Inc. | B | C | B | 16.0x | 6.5% | 15.1% | 181.2% | $187.31 |
| FMSFresenius Medical Care AG | A | D | C | 10.7x | -0.5% | 9.4% | 7.2% | $22.17 |
| PGNYProgyny, Inc. Common Stock | C | B | C | 35.2x | 5.5% | 8.6% | 16.0% | $26.86 |
| AGLagilon health, inc. | B | B | B | — | 0.3% | -5.2% | -110.3% | $85.12 |
| MCTACharming Medical Limited Class A Ordinary Shares | F | F | A | 371.6x | — | 15.4% | — | $29.36 |
| VMDViemed Healthcare, Inc. Common Shares | B | C | C | 24.2x | 25.2% | 7.5% | 10.3% | $9.48 |
| PARKPark Dental Partners, Inc. Common Stock | B | F | C | 17.9x | — | -2.8% | -18.3% | $18.95 |
| CCELCryo-Cell International Inc. | C | D | B | 69.5x | -2.0% | 0.6% | 38.2% | $4.42 |
| MGRXMangoceuticals, Inc. Common Stock | D | F | F | — | -38.9% | -4761.2% | -106.1% | $0.29 |
| BRTXBioRestorative Therapies, Inc. Common Stock (NV) | — | D | F | — | -8.5% | -3975.0% | -423.8% | $1.54 |
About Sotera Health Company Common Stock
Sotera Health Co provides sterilization and analytical testing services for medical devices, pharmaceuticals, and food products. The company operates through three segments: Sterigenics, which dominates revenue through terminal sterilization using gamma irradiation, EO processing, and E-beam technologies; Nordion; and Nelson Labs. Geographically, the company generates primary revenue from the United States, with additional operations in Canada, Europe, and other regions.